文献速递胸部肿瘤

羟氯喹联合铂类双药化疗一线治疗广泛期小细胞肺癌(Study 15):一项随机II期多中心试验

Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial.
PubMed 文献 · Eur J Cancer · 2024-12-06

这项随机多中心II期试验纳入72例未经治疗的广泛期小细胞肺癌患者,按1:1随机分配至羟氯喹(400 mg口服每日两次)联合卡铂-吉西他滨或卡铂-依托泊苷组,或单纯化疗组。羟氯喹未能改善无进展生存期(HR 1.12,95%CI 0.69-1.84;p=0.64);联合组因不良事件完成4周期化疗的患者更少(64% vs 81%),≥3级不良事件更多(83.3% vs 27.8%)。

要点

  • 羟氯喹联合铂类双药化疗未改善广泛期小细胞肺癌的无进展生存期(HR 1.12,95%CI 0.69-1.84;p=0.64)。
  • 中位总生存期联合组8.9个月 vs 单纯化疗组10.2个月(HR 0.83,95%CI 0.48-1.45,p=0.52)。
  • 联合组≥3级不良事件83.3% vs 27.8%,主要为贫血、中性粒细胞减少和血小板减少。

核心结论

  • 在广泛期小细胞肺癌中,羟氯喹联合铂类双药化疗未改善无进展生存期或总生存期,因不良事件增加导致更多患者停止化疗。
  • 结合其他羟氯喹用于癌症的随机研究,证据总体表明羟氯喹作为治疗选择的作用有限。

研究设计与样本

  • 随机多中心II期试验;纳入未经治疗、体能状态0-2分、有可测量病灶的广泛期小细胞肺癌患者。
  • 按1:1随机分配至羟氯喹(400 mg口服每日两次)联合卡铂-吉西他滨或卡铂-依托泊苷组,或单纯化疗组。
  • 化疗最多6周期,羟氯喹同步给药后单药维持最多30个月;主要终点为无进展生存期,目标风险比为0.70。
  • 共72例患者随机(羟氯喹联合化疗36例,单纯化疗36例);羟氯喹中位治疗持续时间4.4个月。

主要发现

  • 羟氯喹未改善无进展生存期(HR 1.12,95%CI 0.69-1.84;p=0.64),中位无进展生存期羟氯喹联合化疗组5.7个月 vs 单纯化疗组6.2个月。
  • 中位总生存期羟氯喹联合化疗组8.9个月 vs 单纯化疗组10.2个月(HR 0.83,95%CI 0.48-1.45,p=0.52)。
  • 因不良事件完成4周期化疗的患者羟氯喹联合化疗组64% vs 单纯化疗组81%。
  • ≥3级不良事件羟氯喹联合化疗组83.3% vs 单纯化疗组27.8%,主要为贫血、中性粒细胞减少和血小板减少,部分与初始较高的吉西他滨剂量有关。

临床怎么用

  • 作者认为,结合其他羟氯喹用于癌症的随机研究,证据总体表明羟氯喹作为治疗选择的作用有限。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most patients with small-cell lung cancer (SCLC) present with extensive-stage (ES) disease and have a poor prognosis despite achieving high initial response rates to platinum-based doublet chemotherapy. This study evaluated whether adding hydroxychloroquine (HCQ) to chemotherapy could improve outcomes. METHODS: This was a randomised multicentre phase II trial. Eligible patients had untreated ES-SCLC, a performance status 0-2 and measurable disease. Patients were randomly assigned (1:1 ratio) to HCQ (400 mg orally twice daily) plus carboplatin-gemcitabine or carboplatin-etoposide alone. Chemotherapy was administered for up to six cycles, with HCQ given concurrently and then as single agent for up to 30 months. Primary endpoint was PFS, aiming for a hazard ratio (HR) of 0.70. RESULTS: 72 patients were randomised (36 HCQ+chemotherapy and 36 chemotherapy alone). Median HCQ treatment duration was 4.4 months. HCQ did not improve PFS (HR 1·12 95 %CI 0·69-1.84; p = 0·64), with a median of 5.7 months (HCQ+chemotherapy) versus 6.2 months (chemotherapy). The corresponding median OS were 8.9 and 10.2 months (HR 0.83, 95 %CI 0.48-1.45, p = 0.52). Fewer patients in the HCQ arm completed four cycles of chemotherapy due to adverse events (64 % vs. 81 %). Grade ≥ 3 adverse events were higher in the HCQ+chemotherapy arm (83.3 % vs. 27.8 %), primarily anaemia, neutropenia, and thrombocytopenia, partly due to the initially higher gemcitabine dose used CONCLUSIONS: Combining HCQ with platinum doublet chemotherapy did not improve PFS or OS outcomes for ES-SCLC, resulting in more patients stopping chemotherapy due to increased adverse events. When considered alongside other randomised studies of HCQ in cancer, the evidence collectively indicates a limited role for HCQ as a therapeutic option.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lee SM, Hewish M, Ahmed S, et al. Hydroxychloroquine in combination with platinum doublet chemotherapy as first-line treatment for extensive-stage small cell lung cancer (Study 15): A randomised phase II multicentre trial. Eur J Cancer. 2024. PMID: 39693892. doi:10.1016/j.ejca.2024.115162

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。